Adaptive biotechnologies stock.
Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.
Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.6. Adaptive Biotechnologies -- $6 a share. Adaptive Biotechnologies ( ADPT 6.95%) may get cheaper in the short-term, but this biotech has an exciting platform that should unlock a lot of value ...
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look ...... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...
BeiGene Ltd. Stock Performance and Financial Outlook: November 2023 Analysis. On November 7, 2023, BeiGene Ltd. (BGNE) experienced some fluctuations in its stock performance. The previous day’s close was recorded at $196.15, and the stock opened at $194.08. Throughout the day, the stock traded within a range of $194.08 to $197.57.
0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $631.55 M by 144.64 M shares outstanding. Adaptive Biotechnologies …Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .
Apr 15, 2022 · Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. The company's stock has been smashed in the last year losing over two-thirds of its share price.
Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.
Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.
The institutional investor acquired 53,400 shares of the company’s stock, corresponding to a value of approximately $472,000. Adaptive Biotechnologies Co., listed on NASDAQ under the symbol ADPT, opened at $6.17 on Tuesday. Over the past year, its stock has ranged between a low of $5.96 and a high of $10.79.Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and …Adaptive Biotechnologies has an immune medicine platform used for sequencing T cells and developing a wide array of diagnostic and clinical products. ... If a stock tanks 80%, ...
Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Feb. 14, 2024 (est.) Last Earnings Release. Nov. 09, 2023. Next Ex-Dividend Date. N/A. Last Ex-Dividend Date. N/A. In depth view into ADPT (Adaptive Biotechnologies) stock including the latest price, news, dividend history, earnings information and financials.
Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive …Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoAdaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. …How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ...Transcript : Adaptive Biotechnologies Corporation, Q4 2022 Earnings Call, Feb 14, 2023 February 14, 2023 at 04:30 pmAdaptive Biotechnologies stock rallies 14% on upgrade to Overweight at Piper Sandler SA News Wed, Dec. 21, 2022 Adaptive Biotechnologies GAAP EPS of -$0.32 beats by $0.06, revenue of $47.8M misses ...
View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …
SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...The upgrade of Adaptive Biotechnologies to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...Nov 30, 2023 · Get Adaptive Biotechnologies Corp (ADPT.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... 12 Feb 2024 / 10:59 AM UTC Q4 2023 ... Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has jumped by 5.72 compared to previous close of 4.37. Despite this, the company has seen a gain of 9.48% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November […]Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive BiotechnologiesAdaptive Biotechnologies Corporation (ADPT) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » ADPT Adaptive …Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...
THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQSEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...Instagram:https://instagram. best trading sites for day tradersmodelo stocknuveen quality municipal income fundtax yield income investment On June 2, David Westenberg at Piper Sandler initiated coverage on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock with a Neutral rating and a target price of $7.50.ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million. ameritrade vslearn how to trade crypto Adaptive Biotechnologies Corp. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:51 p.m. EST Delayed quote $ 4.2000 -0.17 -3.89% After Hours Volume: 4.47K Advanced... professional musician insurance Feb 14, 2023 · Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.28) $ (0.43) $ (1.40) $ (1.48) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 143,054,722 141,228,918 142,515,917 140,354,915 Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...